论文部分内容阅读
多发性骨髓瘤占血液恶性肿瘤的10%,本文系统讲述了初治、难治、复发多发性骨髓瘤(MM)化疗方案的演变过程,介绍了大剂量化疗(HDT)加自体干细胞移植(auto-SCT)以及二次移植新的治疗策略。MP和VAD方案是MM患者的标准治疗方案,大剂量化疗下的骨髓移植改善了患者的生存,但许多患者并不适用此方法治疗,因此需要研制更加有效的、安全的新的试剂,如反应停及其衍生物,蛋白酶抑制剂,三氧化二砷作为单剂治疗或组成联合治疗方案。
Multiple myeloma accounts for 10% of hematological malignancies. This article systematically describes the evolution of chemotherapy-naive, refractory or recurrent multiple myeloma (MM) regimens, and describes the effects of high-dose chemotherapy (HDT) plus autologous stem cell transplantation -SCT) as well as the second transplant new treatment strategy. MP and VAD regimens are the standard treatment for patients with MM. Bone marrow transplants under high-dose chemotherapy improve patient survival, but many patients are not treated with this approach and therefore need to develop more effective and safe new agents such as response Stop and its derivatives, protease inhibitors, arsenic trioxide as a single agent or combination therapy.